Progression-free and overall survival after starting venetoclaxTLS occurrence by dose level and PFS and OS after starting venetoclax. (A) Sankey plot shows what fraction of patients developed TLS at each dose level (DL). Connecting lines show individual patients who changed category, and width of each line is based on number of patients. (B) PFS and OS estimated in Kaplan-Meier curve. Median PFS was 14.1 months (95% CI, 8.1 months to not reached), and 1-year PFS was 56% (95% CI, 35% to 73%). Median OS was not reached, and 1-year OS was 72% (95% CI, 51% to 85%). Median follow-up for PFS was 10.7 months (range, 0.8-22.3 months); for OS, it was 11.1 months (range, 0.8-22.3 months).